![]() | ![]() |
Formats:
|
||||||||||||||||||||||
Copyright © 2008, The American Society for Biochemistry and
Molecular Biology, Inc. Regulation of the Noradrenaline Neurotransmitter Phenotype by the
Transcription Factor
AP-2β* ![]() ‡Molecular Neurobiology Laboratory, McLean Hospital, Harvard Medical School, Belmont, Massachusetts 02478, the §Department of Neurology and Neurobiology, Pharmacology & Physiology, University of Chicago, Chicago, Illinois 60637, and the ¶Institute of Pathology, University Hospital Bonn, D-53127 Bonn, Germany 1Present address: Dept. of Medicinal Herbology, 312 College of Pharmacy,
Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Korea. 2
To whom correspondence should be addressed: Molecular Neurobiology Laboratory,
MRC215, McLean Hospital, Harvard Medical School, 115 Mill St., Belmont, MA
02478. Tel.: 617-855-2024; Fax: 617-855-3479; E-mail:
kskim/at/mclean.harvard.edu.
Received November 6, 2007; Revised February 27, 2008. This article has been cited by other articles in PMC.Abstract AP-2 family transcription factors are essential for development and
morphogenesis of diverse tissues and organs, but their precise roles in
specification of neural crest stem cell (NCSC)-derived cell types have not
been determined. Among three members known to be expressed in the NCSC
(i.e. AP-2α, AP-2β, and AP-2γ), we found that only
AP-2β is predominantly expressed in the sympathetic ganglia of developing
mouse embryos, supporting its role in sympathetic development. Indeed,
AP-2β null mice expressed significantly reduced levels of both
noradrenaline (NA) and NA-synthesizing dopamine β-hydroxylase in the
peripheral nervous system. Strikingly, we also found that NA neuron
development was significantly compromised in the locus coeruleus as well.
Pharmacological treatment with an NA intermediate during pregnancy
significantly rescues the neonatal lethality of AP-2β-/- mice,
indicating that NA deficiency is one of the main causes for lethality found in
AP-2β-/- mice. We also showed that forced expression of
AP-2β, but not other AP-2 factors, in NCSC favors their differentiation
into NA neurons. In summary, we propose that AP-2β plays critical and
distinctive roles in the NA phenotype specification in both the peripheral and
central nervous system during development. A complex regulatory network of extracellular signals and nuclear
transcription factors is involved in the specification of neuronal phenotype
during development in the vertebrate nervous system
(1-3).
Neurotransmitter identity is an important feature among the various phenotypes
of a particular neuron, because it determines the nature of the chemical
neurotransmission a given neuron will mediate and influences the specific
connectivity with target cells. Among various neurotransmitters, noradrenaline
(NA)3 is one of
classical neurotransmitters and controls many essential functions of the
nervous system, including memory, attention, emotion, and autonomic function.
NA is mainly produced from the locus coeruleus (LC) in the central nervous
system (CNS) and the sympathetic ganglia (SG) in the peripheral nervous system
(PNS). NCSCs, which arise from the interface between the neural plate and the
surface epidermis, represent a useful paradigm to understand the molecular
networks involved in cell fate specification because they give rise to diverse
cell types, including the neurons and glia of the PNS, bones, and cartilages
(1,
4-6).
Using NCSC as the primary experimental system, molecular cascades underlying
sympathetic neuronal development and the specification of its NA phenotype
have been extensively studied, leading to identification of critical signals
and transcription factors such as Mash1/Cash1, Phox2a/2b, dHand, and GATA2/3
(reviewed in Refs.
7-9).
Interestingly, most of these transcription factors appear to be unnecessary
for the development of NA neurons in the CNS with the exception of Phox2a/2b,
which are essential for NA neuron development in the LC. However, only Phox2b,
not Phox2a, is indispensable for sympathoadrenergic (SA) development. The AP-2 family proteins are basic helix-span-helix transcription factors
that recognize the palindromic 5′-GCCNNNGGC-3′ motif or its
related GC-rich sequences (reviewed in Refs.
10 and
11). Since the discovery of
AP-2α expressed in the neural crest and neuroectoderm
(12,
13), four additional members,
AP-2β, AP-2γ, AP-2δ, and AP-2ε, have been added to the
AP-2 family
(14-19).
AP-2 proteins share unique structures consisting of an N-terminal
transactivation domain and a C-terminal DNA binding and dimerization domain.
Although AP-2 proteins are coexpressed in some developing organs, they show
different spatiotemporal expression during development, and gene inactivation
studies indicated that they may have quite distinct roles in development
(11). Based on initial studies
of AP-2α and its expression in the neural crest
(12,
13), it was generally assumed
that AP-2α regulates differentiation of neural crest-derived cells such
as SA cells. In line with this notion, mutant zebrafish deficient in
AP-2α (tfAP-2a) showed defect in NA neuron development in both the LC
and sympathetic neurons (20).
However, because AP-2α inactivation in mice causes an early defect
leading to neural tube closure, its precise role for NA neuron development was
not clearly analyzed in mammals
(21,
22). Because AP-2α, AP-2β, and AP-2γ are expressed in migrating
NCSC (11), we speculated that
these three AP-2 family members may play important and distinct roles in
determination of neural crest-derived cell lineages. To address this, we
performed a series of experiments to investigate functional roles of
AP-2α, β, and γ in development of neural crest-derived cell
types, in particular NA neuron development. Strikingly, our gene expression
pattern, loss-of-function, and gain-of-function analyses demonstrate that
AP-2β is important for NA neuron development in the PNS of vertebrates.
Furthermore, development of NA neurons in the CNS was also dependent on
AP-2β. In particular, the lethal phenotype of some AP-2β knock-out
mice could be pharmacologically rescued, strongly suggesting that the NA
deficiency is a proximal cause for the lethality. Taken together, we propose
that AP-2β plays important role(s) in the development of NA neurons of
both the CNS and PNS. EXPERIMENTAL PROCEDURES Animals and DOPS Treatment—Overnight mated female AP-2β
mice (C57B6 background) were tested the next morning for the presence of a
vaginal plug, which was recorded as gestation day 0.5 (E0.5). The embryos were
genotyped by PCR with reverse primer
(5′-TTCTCTGAACTTCGCCCACAGTG-3′) and forward primer
(5′-TTCTTGGGAGGAATGTCAGTCAAC-3′) or
(5′-TGGATGTGGAATGTGTGCGAGG-3′) to detect the wild type or
knock-out loci of AP-2β, respectively. For NA rescue experiment
(23), pregnant mice were
treated with 100 μg/ml of l-phenylephrine and
l-isoproterenol in the drinking water containing 2 mg/ml ascorbic
acid from E8.5 to E16.5. The mice were then administered with DOPS at 2 mg/ml
in the drinking water containing 2 mg/ml ascorbic acid until neonatal day 7
(P7). Toe biopsies were performed on newborn mice for genotyping. Immunohistochemistry and in Situ Hybridization—E10.5-13.5
mouse embryos were fixed overnight in 4% paraformaldehyde in
phosphate-buffered saline at 4 °C. The embryos were treated with 30%
sucrose overnight at 4 °C prior to embedding in OCT compound and stored at
-70 °C. The embryos were sectioned with 16-μm thickness, and
immunohistochemistry or in situ hybridization were performed.
Transverse and parasagittal sections of embryos were used to analyze SG and
LC, respectively. Coronal sections of the brain of newborn mice were used to
analyze LC. The antibodies were detected using the Vectastain kit (Vector
Labs), and the signal was visualized using 3,3′-diaminobenzidine. The
following primary antibodies were used: rabbit anti-TH, 1:2000 for
3,3′-diaminobenzidine and 1:200 for immunofluorescence (Pel-Freeze,
Rodgers, AR); mouse anti-TH, 1:200 for immunofluoroscence (Chemicon, Temecula,
CA); rabbit anti-AP-2α, 1:500 (Santa Cruz Biotechnology, Santa Cruz,
CA); rabbit anti-AP-2β, 1:1000 (Santa Cruz Biotechnology); rabbit
anti-AP-2γ, 1:1000 (Santa Cruz Biotechnology); rabbit anti-DBH, 1:5,000
(gift from Dr. Eipper); and rabbit anti-Phox2b, 1:10,000 (gift from Dr.
Brunet). The specificity of anti-AP-2β antibody was confirmed
(supplemental Fig. S1). For immunofluoroscence microscopy Alex Fluor 488 or
594-conjugated antibodies (Molecular Probes, Carlsbad, CA) were used after
primary antibody treatment. Antisense RNA probes were made from pGEM-Easy T
vector (Promega, Madison, WI) in which PCR products were cloned using primer
sets described in Table 1.
Hybrids with digoxigenin-labeled probes were visualized by treatment with
nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate.
Count of Phox2b-positive Cells and Measurement Expression of TH and DBH
in SG—To measure the size of SG, regions between the forelimbs and
hindlimbs of E13.5 embryos were sectioned with 20-μm thickness. Every tenth
section was collected and stained with Phox2b-specific antibodies. Total
Phox2b-positive cells in the SG from the collected sections were counted. The
trunk regions of E13.5 embryos were sectioned with 16-μm thickness. Then
expression of TH and DBH was detected by their specific antibodies and
visualized using 3,3′-diaminobenzidine as described in the previous
section. The intensity of signal was measured using the National Institutes of
Health Image program (ImageJ). At least four different sections in each embryo
were analyzed. NA Measurement—E16.5 embryos or brains from newborn mice
were frozen and stored at -70 °C. The samples were homogenized in the
presence of 0.2 m perchloric acid and 0.1 mm EDTA. The
samples were disrupted by ultrasonication and centrifuged at 13,000 rpm for 15
min at 4 °C. The supernatants were extracted with a syringe filter and
used to measure the amount of NA by HPLC. The pellets were resuspended in
phosphate buffer (10 mm potassium phosphate containing 0.2% Triton
X-100), and the amount of protein was determined. NCSC Cultures—Full-length AP-2α, AP-2β, and
AP-2γ cDNA was cloned into pSlax13
(24). The cDNAs were cloned
into the ClaI site of RCASBP, an avian replication-competent retroviral vector
(24). The viruses were made in
DF1 chicken fibroblast cells (ATCC), and titers were determined using the
anti-gag protein monoclonal antibody AMV-3C2 (Developmental Studies Hybridoma
Bank, Iowa, IA) (25). Primary
culture of the trunk region of quail eggs (Conturnix japonica, CBT
Farms, Chestertown, MD) was performed as described
(25). NCSC from the trunk
region were infected with each RCAS virus at a multiplicity of infection of 5.
After 7 days in culture, the neural crest cells were analyzed by quantitative
real time PCR or immunohistochemistry. Quantitative Real Time PCR Analysis—cDNA was made from 5
μg of total RNA, which was isolated using TRIzol reagent (Sigma), using
Superscript II (Invitrogen) with oligo(dT)12-18 as primer. Real
time PCR analyses were performed in duplicate using SYBR green I using DNA
engine Opticon™ (MJ Research, Waltham, MA) to analyze mRNA expression
levels. The primer sets used to detect mRNA are shown in Tables
1 and
2.
RESULTS Transcription Factor AP-2β Is Specifically Expressed in
the SG of Early Chick and Mouse Embryos—Although AP-2α,
β, and γ are expressed in NCSC, their specific roles in neural
crest-derived cell lineages are not known. To investigate the potential roles
of AP-2 family transcription factors, we analyzed the expression patterns of
these factors in developing embryos. Notably, our immunohistochemistry
analyses showed that only AP-2β was prominently expressed in the SG of
E13.5 mouse embryos (Fig. 1, A and
B
Development and Neurotransmitter Phenotype Specification of NA Neurons
Are Compromised in AP-2β Null Mice—To further
investigate the role of AP-2β in SA neuronal development as well as in NA
phenotype specification in vivo, we tested whether NA neurons exhibit
any developmental abnormalities in the AP-2β-/- mouse.
Although previous knock-out studies revealed the critical role of AP-2β
in kidney development (27),
its role for the nervous system development is not known. We isolated the
trunk regions and hind-brains of embryos to investigate noradrenergic
lineage-specific gene expression in the PNS and CNS, respectively.
Quantitative real time PCR analysis demonstrated that the expression of DBH
mRNA was reduced by ~78% in the PNS of AP-2β-/- embryos
compared with their wild type littermates
(Fig. 2A
Surprisingly, we found that DBH mRNA expression was even more dramatically
diminished in the hindbrain of AP-2β-/- embryos (Figs.
(Figs.2B2B
DOPS Treatment during Pregnancy Significantly Rescues the Neonatal
Lethality of AP-2β-/-
Mice—AP-2β-/- mice die during neonatal days 1
and 2, and this lethality has been attributed to kidney failure
(27). In our hands, a small
fraction (~10%) of newborn AP-2β-/- mice survive beyond
P2, but none of them survived past P20
(Fig. 6A
Exogenous Expression of AP-2β in NCSC Favors Their
Differentiation to SA Cells—To further investigate the functional
role of AP-2β, we next attempted the gain-of-function approach.
Specifically, we tested whether forced expression of AP-2β would
distinctively increase the formation of SA cells in quail primary NCSC using
avian-specific RCAS viruses
(25). In parallel, we also
tested RCAS viruses that express AP-2α or AP-2γ because they are
also known to be expressed in the neural crest. We speculated that NCSC will
likely provide the appropriate cellular context because they were previously
shown to be able to differentiate into various neural crest derivatives, such
as SA neurons and melanocytes
(29). Following transduction
of NCSC with RCAS viruses, the cells were cultured for 7 days, and SA cell
differentiation was examined by immunocytochemistry and real time PCR
analyses, whereas differentiation of melanocytes was assessed by the
appearance of pigmentation. Forced expression of AP-2β in NCSC resulted
in a 4-fold increase in the number of SA cells
(Fig. 7, G and
I
DISCUSSION AP-2β Critically Regulates the NA Neurotransmitter
Phenotype in Both the PNS and the CNS of Vertebrates—In the nervous
system NA controls many essential functions such as memory, attention,
emotion, and autonomic function, and its abnormal metabolism is implicated in
diverse human diseases. Major NA neurons reside in the LC of the CNS and in
the SG of the PNS. In this study, we provide several lines of evidence that
AP-2β regulates development and phenotype specification of NA neurons in
both the CNS and PNS. First, among members of the AP-2 family, AP-2β is
predominantly expressed in the SG of mouse embryos, and its expression
completely coincides with that of the sympathetic neuronal marker, TH. Second,
in AP-2β null mice, development of NA neurons appears to be partially
defective in the SG of the PNS as well as in the LC of the CNS. In addition,
levels of NA, NA-synthesizing enzyme DBH, and the number of NA neurons are
significantly diminished in the SG and in the LC. Third, we found that
neonatal lethality observed in AP-2β null mice is due, in part, to
deficiency of NA because we were able to alleviate their neonatal lethality by
treating pregnant females with DOPS. Finally, our forced expression studies
showed that AP-2β favors differentiation of chick NCSC to the SA cell
fate, whereas AP-2α appears to play a role in melanocyte
differentiation. Taken together, our gene expression studies,
loss-of-function, and gain-of-function analyses strongly indicate that
AP-2β plays a critical role, probably in conjunction with additional
transcription factors (see below), in the development and neurotransmitter
specification of NA neurons of both the CNS and the PNS. Distinctive Roles of AP-2 Transcription Factors for Differentiation of
Diverse Neural Crest-derived Cell Lineages—The AP-2 family
transcription factors play essential roles for development and morphogenesis
of diverse tissues and organs. In mammalian species, e.g. human and
rodents, five members of AP-2 factors (α-ε) have been reported
(11). Among three AP-2 members
(AP-2α, β, and γ) expressed in the nervous system, we show
that AP-2β specifically regulates development of NA neurons. These
results are rather surprising because previous in vitro studies from
this and other laboratories showed that AP-2α regulates SA-specific gene
promoters such as TH, DBH, and phenylethanolamine N-methyltransferase
(30-32).
Nevertheless, using the gain-of-function analyses, we found that AP-2-α,
β, and γ exhibit clearly distinctive roles in cell fate
determination of NCSC. Whereas AP-2α appears to play an important role
in melanocyte differentiation from NCSC, AP-2β favors differentiation of
NCSC to the SA cell fate. In contrast, exogenous expression of AP-2γ did
not affect generation of melanocyte or SA cells. Therefore, it seems that
these AP-2 family transcription factors may have very distinctive mechanisms
in vivo despite the fact that they can similarly transactivate the
promoter activities in vitro. Indeed, all three factors
(AP-2-α, β, and γ) exhibited similar transactivation and DNA
binding activities in vitro to the TH and DBH promoters (data now
shown). However, we cannot exclude the possible role of other AP-2 proteins,
which may be expressed in a specific stage during development, in the
differentiation of neural crest-derived SA lineages. Strikingly, our
gain-of-function results showed that AP-2α dramatically favors
melanocyte formation from NCSC at the expense of SA cells, which is consistent
with the recent AP-2α conditional knock-out studies showing that
AP-2α is critical for melanocyte differentiation
(33). These findings are
intriguing when considering the finding that human melanoma is associated with
a loss of AP-2α (34) and
suggest the possibility that AP-2α may have a crucial role in
controlling both differentiation and maintenance of melanocytes. Notably, in
the mutant zebrafish lacking AP-2α (tfAP-2a), NA neurons could not
develop properly in both the LC and sympathetic neurons
(20). Thus, tfAP-2a of
zebrafish may represent a functional counterpart (orthologue) of AP-2β of
vertebrates like mouse for NA neuron development. Transcriptional Regulatory Cascade of NA Neuron Development in the CNS
and PNS—During the last decade, important extracellular signals and
critical transcription factors controlling NA neuronal cell fate
determination, including sympathetic neurons from NCSC, have been identified
(1,
4,
8,
9). Such transcription factors
include Mash1 (Cash1), Phox2a/2b, GATA2/3, and dHand
(7-9,
35,
36). Among these key
transcription factors, Phox2b is unique because it is required for NA neuron
development in both the CNS and PNS, rendering it a master regulator of the NA
phenotype. In contrast, other factors (e.g. Mash1, GATA3/2, and
dHand) appear to be important for NA neurons in the PNS, whereas Phox2a is
required for the development of central NA neurons in the LC
(7-9,
35,
37,
38). Notably, Phox2b is
critical not only for the NA phenotype but also for earlier neurogenesis and
patterning (7,
9). Thus, the role of Phox2b is
not limited to NA neurons but also controls the development of wider
structures such as all autonomic ganglia (sympathetic, parasympathetic, and
enteric), cranial sensory ganglia, adrenal, and extra-adrenal chromaffin
cells, strongly supporting that it coordinates general as well as
subtype-specific aspects of these neurons as an essential proneural gene.
Similarly, other classic basic helix-loop-helix proneural gene such as Olig2
is known to couple general and subtype-specific identity in motor neuron
development (39,
40). More recently, another
basic helix-loop-helix proneural gene Neurogenin 2 and the homeodomain factor
Lmx1a have been shown to be expressed in proliferating dopaminergic precursors
and regulate the development of mid-brain dopamine neurons
(41-43).
Our results indicate that AP-2β is required for proper NA neuron
development in both the CNS and the PNS. However, it appears that AP-2β
functions at later stages of development and controls more specifically the
neuronal subtype identities, instead of general neurogenesis and the
pan-neuronal aspects. For example, the earlier development of the SG was only
marginally defective and its abnormality becomes progressively more evident.
Therefore, AP-2β likely coordinates with these transcription factors
(e.g. Phox2a/2b, Mash1, GATA3/2, and dHand) to regulate the cascade
of NA neuron development in the CNS and PNS. Further investigation of
AP-2β function and its ontogenetic relations to upstream signaling
molecules and other key transcription factors will provide deeper insights on
the regulatory cascade underlying the development of NA neurons in the CNS and
PNS. Acknowledgments We thank Jackie Lee at the University of Colorado at Boulder for critical
reading of this manuscript, Jean-François Brunet for anti-Phox2b
antibody, Betty Eipper for anti-DBH antibody, Steven Thomas at the University
of Pennsylvania, and David Robertson at the University of Vanderbilt for the
DOPS treatment experiment. Notes *This work was supported, in whole or in part, by National
Institutes of Health Grants
MH48866 and DC006501. This work
was also supported by an International Grant from the Brain
Research Center funded by the Korean Ministry
of Science and Technology (to K. S. K.), by
Korea Research Foundation Grant
KRF-2006-214-E00037 (to M. S. O.), and by a grant from
the Deutsche Forschungsgemeinschaftand (to R.
B.). The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
“advertisement” in accordance with 18 U.S.C. Section 1734
solely to indicate this fact. The on-line version of this article (available at
http://www.jbc.org)
contains supplemental Table S1 and supplemental Figs. S1-S3. Footnotes 3The abbreviations used are: NA, noradrenaline; NCSC, neural crest stem
cell; SG, sympathetic ganglia; DBH, dopamine β-hydroxylase; PNS,
peripheral nervous system; CNS, central nervous system; LC, locus coeruleus;
SA, sympathoadrenergic; DOPS, l-3,4-dihydroxyphenylserine;
En, embryonic day n;Pn, postnatal day n;
TH, tyrosine hydroxylase; HPLC, high performance liquid chromatography; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase. References 1. Anderson, D. J. (1997. ) Trends
Genet. 13
276-280 [PubMed] 2. Edlund, T., and Jessell, T. M. (1999. )
Cell 96
211-224 [PubMed] 3. Marquardt, T., and Pfaff, S. L. (2001. )
Cell 106
651-654 [PubMed] 4. Bronner-Fraser, M. (2002. ) J. Physiol.
(Paris) 96
3-8 [PubMed] 5. Sauka-Spengler, T., and Bronner-Fraser, M. (2006. )
Curr. Opin. Genet. Dev.
16 360-366 [PubMed] 6. Huber, K. (2006. ) Dev. Biol.
298
335-343 [PubMed] 7. Brunet, J. F., and Pattyn, A. (2002. ) Curr.
Opin. Genet. Dev. 12
435-440 [PubMed] 8. Howard, M. J. (2005. ) Dev.
Biol. 277
271-286 [PubMed] 9. Goridis, C., and Rohrer, H. (2002. ) Nat.
Rev. Neurosci. 3
531-541 [PubMed] 10. Hilger-Eversheim, K., Moser, M., Schorle, H., and Buettner, R.
(2000. ) Gene (Amst.)
260 1-12 [PubMed] 11. Eckert, D., Buhl, S., Weber, S., Jager, R., and Schorle, H.
(2005. ) Genome Biol.
6 246. [PubMed] 12. Williams, T., Admon, A., Luscher, B., and Tjian, R.
(1988. ) Genes Dev.
2
1557-1569 [PubMed] 13. Mitchell, P. J., Timmons, P. M., Hebert, J. M., Rigby, P. W., and
Tjian, R. (1991. ) Genes Dev.
5 105-119 [PubMed] 14. Moser, M., Imhof, A., Pscherer, A., Bauer, R., Amselgruber, W.,
Sinowatz, F., Hofstadter, F., Schule, R., and Buettner, R. (1995. )
Development 121
2779-2788 [PubMed] 15. Chazaud, C., Oulad-Abdelghani, M., Bouillet, P., Decimo, D.,
Chambon, P., and Dolle, P. (1996. ) Mech.
Dev. 54
83-94 [PubMed] 16. Oulad-Abdelghani, M., Bouillet, P., Chazaud, C., Dolle, P., and
Chambon, P. (1996. ) Exp. Cell Res.
225
338-347 [PubMed] 17. Zhao, F., Satoda, M., Licht, J. D., Hayashizaki, Y., and Gelb, B.
D. (2001. ) J. Biol. Chem.
276
40755-40760 [PubMed] 18. Wang, H. V., Vaupel, K., Buettner, R., Bosserhoff, A. K., and
Moser, M. (2004. ) Dev. Dyn.
231
128-135 [PubMed] 19. Feng, W., and Williams, T. (2003. ) Mol. Cell
Neurosci. 24
460-475 [PubMed] 20. Holzschuh, J., Barrallo-Gimeno, A., Ettl, A. K., Durr, K., Knapik,
E. W., and Driever, W. (2003. ) Development
130
5741-5754 [PubMed] 21. Schorle, H., Meier, P., Buchert, M., Jaenisch, R., and Mitchell, P.
J. (1996. ) Nature
381
235-238 [PubMed] 22. Zhang, J., Hagopian-Donaldson, S., Serbedzija, G., Elsemore, J.,
Plehn-Dujowich, D., McMahon, A. P., Flavell, R. A., and Williams, T.
(1996. ) Nature
381
238-241 [PubMed] 23. Thomas, S. A., Marck, B. T., Palmiter, R. D., and Matsumoto, A. M.
(1998. ) J. Neurochem.
70
2468-2476 [PubMed] 24. Logan, M., and Tabin, C. (1998. )
Methods 14
407-420 [PubMed] 25. Hong, S. J., Huh, Y., Chae, H., Hong, S., Lardaro, T., and Kim, K.
S. (2006. ) J. Neurochem.
98 773-781 [PubMed] 26. Moser, M., Ruschoff, J., and Buettner, R. (1997. )
Dev. Dyn. 208
115-124 [PubMed] 27. Moser, M., Pscherer, A., Roth, C., Becker, J., Mucher, G., Zerres,
K., Dixkens, C., Weis, J., Guay-Woodford, L., Buettner, R., and Fassler, R.
(1997. ) Genes Dev.
11
1938-1948 [PubMed] 28. Ichikawa, H., Mo, Z., Xiang, M., and Sugimoto, T.
(2005. ) Brain Res.
1036
192-195 [PubMed] 29. Knecht, A. K., and Bronner-Fraser, M. (2002. )
Nat. Rev. Genet. 3
453-461 [PubMed] 30. Ebert, S. N., Ficklin, M. B., Her, S., Siddall, B. J., Bell, R. A.,
Ganguly, K., Morita, K., and Wong, D. L. (1998. ) J.
Neurochem. 70
2286-2295 [PubMed] 31. Greco, D., Zellmer, E., Zhang, Z., and Lewis, E.
(1995. ) J. Neurochem.
65 510-516 [PubMed] 32. Kim, H. S., Hong, S. J., LeDoux, M. S., and Kim, K. S.
(2001. ) J. Neurochem.
76 280-294 [PubMed] 33. Brewer, S., Feng, W., Huang, J., Sullivan, S., and Williams, T.
(2004. ) Dev. Biol.
267
135-152 [PubMed] 34. Tellez, C., McCarty, M., Ruiz, M., and Bar-Eli, M.
(2003. ) J. Biol. Chem.
278
46632-46642 [PubMed] 35. Lim, K. C., Lakshmanan, G., Crawford, S. E., Gu, Y., Grosveld, F.,
and Engel, J. D. (2000. ) Nat. Genet.
25 209-212 [PubMed] 36. Morikawa, Y., D'Autreaux, F., Gershon, M. D., and Cserjesi, P.
(2007. ) Dev. Biol.
307
114-126 [PubMed] 37. Coppola, E., Pattyn, A., Guthrie, S. C., Goridis, C., and Studer,
M. (2005. ) EMBO J.
24
4392-4403 [PubMed] 38. Lucas, M. E., Muller, F., Rudiger, R., Henion, P. D., and Rohrer,
H. (2006. ) Development
133
4015-4024 [PubMed] 39. Novitch, B. G., Chen, A. I., and Jessell, T. M. (2001. )
Neuron 31
773-789 [PubMed] 40. Mizuguchi, R., Sugimori, M., Takebayashi, H., Kosako, H., Nagao,
M., Yoshida, S., Nabeshima, Y., Shimamura, K., and Nakafuku, M.
(2001. ) Neuron
31 757-771 [PubMed] 41. Andersson, E., Tryggvason, U., Deng, Q., Friling, S., Alekseenko,
Z., Robert, B., Perlmann, T., and Ericson, J. (2006. )
Cell 124
393-405 [PubMed] 42. Andersson, E., Jensen, J. B., Parmar, M., Guillemot, F., and
Bjorklund, A. (2006. ) Development
133
507-516 [PubMed] 43. Kele, J., Simplicio, N., Ferri, A. L., Mira, H., Guillemot, F.,
Arenas, E., and Ang, S. L. (2006. )
Development 133
495-505 [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||
Trends Genet. 1997 Jul; 13(7):276-80.
[Trends Genet. 1997]Cell. 2001 Sep 21; 106(6):651-4.
[Cell. 2001]J Physiol Paris. 2002 Jan-Mar; 96(1-2):3-8.
[J Physiol Paris. 2002]Dev Biol. 2006 Oct 15; 298(2):335-43.
[Dev Biol. 2006]Curr Opin Genet Dev. 2002 Aug; 12(4):435-40.
[Curr Opin Genet Dev. 2002]Gene. 2000 Dec 30; 260(1-2):1-12.
[Gene. 2000]Genome Biol. 2005; 6(13):246.
[Genome Biol. 2005]Genes Dev. 1988 Dec; 2(12A):1557-69.
[Genes Dev. 1988]Genes Dev. 1991 Jan; 5(1):105-19.
[Genes Dev. 1991]Development. 1995 Sep; 121(9):2779-88.
[Development. 1995]Genome Biol. 2005; 6(13):246.
[Genome Biol. 2005]J Neurochem. 1998 Jun; 70(6):2468-76.
[J Neurochem. 1998]Methods. 1998 Apr; 14(4):407-20.
[Methods. 1998]J Neurochem. 2006 Aug; 98(3):773-81.
[J Neurochem. 2006]Development. 1995 Sep; 121(9):2779-88.
[Development. 1995]Dev Dyn. 1997 Jan; 208(1):115-24.
[Dev Dyn. 1997]Genes Dev. 1997 Aug 1; 11(15):1938-48.
[Genes Dev. 1997]Brain Res. 2005 Mar 2; 1036(1-2):192-5.
[Brain Res. 2005]Genes Dev. 1997 Aug 1; 11(15):1938-48.
[Genes Dev. 1997]Gene. 2000 Dec 30; 260(1-2):1-12.
[Gene. 2000]J Neurochem. 2006 Aug; 98(3):773-81.
[J Neurochem. 2006]Nat Rev Genet. 2002 Jun; 3(6):453-61.
[Nat Rev Genet. 2002]Genome Biol. 2005; 6(13):246.
[Genome Biol. 2005]J Neurochem. 1998 Jun; 70(6):2286-95.
[J Neurochem. 1998]J Neurochem. 2001 Jan; 76(1):280-94.
[J Neurochem. 2001]Dev Biol. 2004 Mar 1; 267(1):135-52.
[Dev Biol. 2004]J Biol Chem. 2003 Nov 21; 278(47):46632-42.
[J Biol Chem. 2003]Trends Genet. 1997 Jul; 13(7):276-80.
[Trends Genet. 1997]J Physiol Paris. 2002 Jan-Mar; 96(1-2):3-8.
[J Physiol Paris. 2002]Dev Biol. 2005 Jan 15; 277(2):271-86.
[Dev Biol. 2005]Nat Rev Neurosci. 2002 Jul; 3(7):531-41.
[Nat Rev Neurosci. 2002]Curr Opin Genet Dev. 2002 Aug; 12(4):435-40.
[Curr Opin Genet Dev. 2002]